{"id":"oral-ir-ld-cd","safety":{"commonSideEffects":[{"rate":null,"effect":"Dyskinesia"},{"rate":null,"effect":"Motor fluctuations"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Orthostatic hypotension"}]},"_chembl":{"chemblId":"CHEMBL2108778","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levodopa is a dopamine precursor that crosses the blood-brain barrier and is converted to dopamine by aromatic amino acid decarboxylase. Carbidopa is a peripheral decarboxylase inhibitor that prevents premature conversion of levodopa in the periphery, allowing more levodopa to reach the brain. The immediate-release formulation with low-dose carbidopa provides rapid symptom relief for Parkinson's motor fluctuations.","oneSentence":"Oral IR-LD/CD is a levodopa/carbidopa combination that increases dopamine levels in the brain by delivering levodopa with carbidopa, a decarboxylase inhibitor, to treat motor symptoms of Parkinson's disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:24:42.831Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease motor fluctuations and wearing-off phenomena"}]},"trialDetails":[{"nctId":"NCT04006210","phase":"PHASE3","title":"Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations","status":"ACTIVE_NOT_RECRUITING","sponsor":"NeuroDerm Ltd.","startDate":"2019-09-30","conditions":"Parkinson's Disease","enrollment":381},{"nctId":"NCT02577523","phase":"PHASE2","title":"A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2015-12-29","conditions":"Parkinson's Disease","enrollment":38},{"nctId":"NCT03670953","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2018-11-06","conditions":"Parkinson's Disease (Disorder)","enrollment":630},{"nctId":"NCT01411137","phase":"PHASE3","title":"Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2011-08","conditions":"Parkinson's Disease","enrollment":43},{"nctId":"NCT02605434","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients","status":"UNKNOWN","sponsor":"Intec Pharma Ltd.","startDate":"2016-03","conditions":"Parkinson's Disease","enrollment":420}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["IR-LD/CD"],"phase":"phase_3","status":"active","brandName":"Oral IR-LD/CD","genericName":"Oral IR-LD/CD","companyName":"NeuroDerm Ltd.","companyId":"neuroderm-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oral IR-LD/CD is a levodopa/carbidopa combination that increases dopamine levels in the brain by delivering levodopa with carbidopa, a decarboxylase inhibitor, to treat motor symptoms of Parkinson's disease. Used for Parkinson's disease motor fluctuations and wearing-off phenomena.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}